We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Former MannKind GCP Official Alleges Clinical Trial Fraud
Former MannKind GCP Official Alleges Clinical Trial Fraud
November 10, 2010
Less than two months prior to the FDA’s user fee action date on its inhaled insulin Afrezza, MannKind is facing allegations of clinical trial improprieties from a former employee.